Abstract
Integrin-linked kinase (ILK) is an ankyrin repeat-containing serine-threonine protein kinase that is involved in the regulation of integrin-mediated processes such as cancer cell proliferation, migration and invasion. In this study, we examined the effect of a lentivirus-mediated knockdown of ILK on the proliferation, migration and invasion of pancreatic cancer (Panc-1) cells. Immunohistochemical staining showed that ILK expression was enhanced in pancreatic cancer tissue. The silencing of ILK in human Panc-1 cells led to cell cycle arrest in the G0/G1 phase and delayed cell proliferation, in addition to down-regulating cell migration and invasion. The latter effects were mediated by up-regulating the expression of E-cadherin, a key protein in cell adhesion. These findings indicate that ILK may be a new diagnostic marker for pancreatic cancer and that silencing ILK could be a potentially useful therapeutic approach for treating pancreatic cancer.
Highlights
Pancreatic cancer is one of the most lethal cancers, with 5-year survival rates averaging less than 5% (Shaib et al, 2006)
In contrast to pancreatic tissue, 88.5% and 100% of the adjacent and normal tissue samples, respectively, showed no integrin-linked kinase (ILK) expression. These findings indicate that ILK expression was enhanced in pancreatic cancer tissue compared to normal and adjacent pancreatic tissues
room temperature (RT)-PCR showed that the ILK mRNA levels in ILK small interfering RNA (siRNA)-infected cells (KD) were significantly lower than in cells infected with pGCSIL-shNC (NC) (Figure 2B)
Summary
Pancreatic cancer is one of the most lethal cancers, with 5-year survival rates averaging less than 5% (Shaib et al, 2006). Several chemotherapeutic agents are active against pancreatic cancer, there is still no satisfactory chemical treatment for this disease (Yoganathan et al, 2000; Chen et al, 2010). Surgery is still the most effective treatment for pancreatic cancer. Surgery is not possible because the cancer cells have already invaded other tissues by the time of diagnosis. Less than 20% of the patients undergo surgical treatment, with the remainder receiving chemotherapy and/or radiotherapy, both of which are associated with serious side effects (Gunaratnam et al, 2001). The development of new treatments with fewer side effects is an important area of pancreatic cancer research
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
